Bruce Booth, Director at Kymera Therapeutics, Inc. (KYMR), sold 76,650 shares at $105.78 ($8.3M) on 2026-06-29, disclosed to the SEC on 2026-07-02.
Scheduled sale ($8.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.78 | 770 | $81K | 1.0% |
| 2 | $105.78 | 5,549 | $587K | 7.1% |
| 3 | $106.63 | 2,133 | $227K | 2.7% |
| 4 | $106.63 | 14,798 | $1.6M | 19.1% |
| 5 | $107.76 | 19,419 | $2.1M | 25.3% |
| 6 | $107.76 | 2,698 |
| $291K |
| 3.5% |
| 7 | $108.28 | 10,848 | $1.2M | 14.2% |
| 8 | $108.28 | 1,498 | $162K | 2.0% |
| 9 | $109.75 | 7,968 | $874K | 10.6% |
| 10 | $109.75 | 1,104 | $121K | 1.5% |
| 11 | $110.67 | 1,078 | $119K | 1.4% |
| 12 | $110.67 | 7,723 | $855K | 10.3% |
| 13 | $111.20 | 130 | $14K | 0.2% |
| 14 | $111.20 | 934 | $104K | 1.3% |
| Total | $108.05 avg | 76,650 | $8.3M | 100% |
| Filing → |
| KYMR | SELL | 2026-06-25 | $34.8M | — | Filing → |
| KYMR | SELL | 2026-06-25 | $44.0M | — | Filing → |
| KYMR | SELL | 2026-06-22 | $45.3M | — | Filing → |